Transaction in Own Shares

PureTech Health PLC

18 September 2023

 

18 September 2023

PureTech Health plc

Transaction in Own Shares

PureTech Health PLC (the "Company") announces that it has purchased the following number of its ordinary shares of one pence each through Jefferies International Limited ("Jefferies"), as part of its Share Buyback Programme, details of which were announced on 9 May 2022.

Date of purchase:	15 September 2023
Number of ordinary shares purchased:	4,718
Highest price paid per share:	216.00p
Lowest price paid per share:	215.00p
Volume weighted average price paid per share:	215.91p

PureTech intends to retain the purchased shares in treasury.

Following the above transaction, the Company will have 14,495,951 ordinary shares in treasury and has 274,972,208 ordinary shares in issue (excluding treasury shares). The total number of voting rights in the Company is therefore 274,972,208 which may be used by shareholders in their calculations to determine if they are required to notify their interest in, or a change to their interest in, PureTech Health plc under the FCA's Disclosure Guidance and Transparency Rules.

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018) (the Market Abuse Regulation), detailed information about the individual purchases is available below.

About PureTech Health

PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 27 therapeutics and therapeutic candidates, including two (Plenity® and EndeavorRx®) that have received both U.S. FDA clearance and European marketing authorization and a third (KarXT) that is expected to be filed soon for FDA approval. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration enabling studies. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points.

For more information, visit www.puretechhealth.com or connect with us on Twitter @puretechh.

Contact:

PureTech

Investor Relations

[e-mail]

Individual Transactions

Transaction Date	Transaction Time	Volume	Price (GBp)	Platform	Transaction Reference Number
15/09/2023	10:05:43	285	216	XLON	00369403109TRLO1.1.1
15/09/2023	09:57:16	38	215.5	CHIX	00369401309TRLO1.1.1
15/09/2023	09:57:05	285	216	XLON	00369401273TRLO1.1.1
15/09/2023	09:48:17	285	216	XLON	00369399446TRLO1.1.1
15/09/2023	09:41:36	285	216	XLON	00369397928TRLO1.1.1
15/09/2023	09:39:37	2280	216	XLON	00369397510TRLO1.1.1
15/09/2023	09:39:28	285	216	XLON	00369397486TRLO1.1.1
15/09/2023	09:30:36	285	216	XLON	00369394924TRLO1.1.1
15/09/2023	09:28:20	285	216	XLON	00369394210TRLO1.1.1
15/09/2023	08:27:48	36	215.5	CHIX	00369382770TRLO1.1.1
15/09/2023	08:16:54	36	215	CHIX	00369379869TRLO1.1.1
15/09/2023	08:06:03	35	215	CHIX	00369377400TRLO1.1.1
15/09/2023	08:05:58	17	215	AQXE	00369377322TRLO1.1.1
15/09/2023	08:05:53	281	215	XLON	00369377317TRLO1.1.1

 

END